Modality
ADC
MOA
PD-1i
Target
IL-17A
Pathway
Innate Imm
MSRCCPAH
Development Pipeline
Preclinical
~Feb 2015
→ ~May 2016
Phase 1
~Aug 2016
→ ~Nov 2017
Phase 2
Feb 2018
→ Mar 2028
Phase 2Current
NCT04819423
2,370 pts·RCC
2018-02→2028-03·Terminated
2,370 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-03-272.0y awayPh2 Data· RCC
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P2
Termina…
Catalysts
Ph2 Data
2028-03-27 · 2.0y away
RCC
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04819423 | Phase 2 | RCC | Terminated | 2370 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| RVM-7089 | Revolution Medicines | Phase 3 | IL-17A | |
| Adagrarapivir | Ideaya Bio | Phase 1/2 | IL-17A | |
| ZYM-2450 | Zymeworks | Phase 2 | GLP-1R | |
| Polazanubrutinib | Tango Ther | Phase 1 | IL-17A |